Cancer Patients Face Higher Long-Term Death Risk After Mitral Valve Clip Repair, Major Analysis Finds

For millions of people living with both cancer and a leaky mitral valve, one of the most consequential decisions in modern cardiology is whether to undergo a minimally invasive valve repair. A new systematic review and meta-analysis published in GeroScience has now delivered the most comprehensive picture yet of what happens to these patients in the years following transcatheter mitral valve repair, a catheter-based procedure often known by its abbreviation M-TEER. The findings are striking: while patients with cancer do just as well as those without cancer in the immediate aftermath of the procedure, their long-term risk of dying is significantly higher, a disparity that emerges only over the months and years of follow-up.

The research team, led by Filippo Biondi and Rosalinda Madonna of the University of Pisa along with collaborators from institutions across Italy, systematically searched PubMed and Scopus databases following the PRISMA 2020 reporting guidelines. The protocol was prospectively registered in PROSPERO, the international registry for systematic review protocols, under registration number CRD420261368392. From the initial search, eight observational studies met the strict inclusion criteria, which required studies to report outcomes of either transcatheter or surgical mitral valve interventions in patients with active or prior cancer. Seven of these studies evaluated M-TEER specifically, and they accounted for the overwhelming majority of patients in the quantitative analysis: 1,522 patients with cancer and 4,716 controls without cancer.

The technical centerpiece of the analysis was the pooling of hazard ratios using random-effects models, the standard statistical approach when studies are expected to differ in their populations and methods. Where hazard ratios were not directly reported by the original studies, the researchers reconstructed them from published survival data using established methods for time-to-event synthesis, including techniques that extract individual-level survival estimates from published Kaplan-Meier curves. This methodological rigor matters because it allowed the team to combine evidence from heterogeneous observational cohorts into a single, statistically coherent estimate of the mortality risk attributable to cancer.

The headline result is unambiguous. In the pooled analysis of M-TEER studies, having cancer was associated with a 72 percent higher risk of all-cause mortality during follow-up, with a hazard ratio of 1.72 and a 95 percent confidence interval of 1.03 to 2.90. The confidence interval, while wide, excludes the null value of 1.0, indicating a statistically significant association. The degree of statistical heterogeneity between studies, measured by the I-squared statistic, was 74.8 percent, which is substantial and signals that the individual studies varied considerably in their populations and effect sizes. Importantly, the association remained consistent across prespecified subgroup and sensitivity analyses, suggesting the finding is not driven by any single outlier study.

What makes the result clinically fascinating is the contrast between short-term and long-term outcomes. The analysis found no significant differences between patients with and without cancer in 30-day mortality or in procedural success, meaning the catheter-based repair itself appears to work equally well in both groups. The clip-based edge-to-edge repair, which approximates the leaflets of the mitral valve using a device delivered through a vein in the leg, is far less invasive than open-heart surgery and has become the treatment of choice for patients deemed too frail or high-risk for conventional surgery. Cancer patients, who often fall precisely into this high-risk category, appear to derive the same immediate procedural benefit as anyone else.

So why do cancer patients die more often in the years that follow? The authors are careful to note that their evidence does not establish the factors responsible for this excess mortality. They outline several plausible mechanisms that future research must disentangle. Frailty, the age-related decline in physiological reserve, is more common in cancer patients and independently predicts death after cardiac procedures. Cardiovascular comorbidity, including pre-existing heart failure and coronary disease, may be more advanced in cancer patients by the time they reach the catheterization laboratory. Treatment-related comorbidity is another candidate: chemotherapy agents such as anthracyclines and targeted therapies like trastuzumab can injure the heart muscle, while chest radiation is a well-established cause of valvular heart disease, stiffening and calcifying the very valves that later require repair. The characteristics of the mitral regurgitation itself, whether it is degenerative or secondary to heart failure, may also differ between the groups, as may other residual confounders that observational data cannot fully adjust for.

One particularly intriguing detail from the analysis is that studies comparing matched cohorts found a non-significant difference in the hazard ratio for long-term mortality. Propensity matching, a statistical technique that pairs cancer patients with non-cancer patients of similar age, comorbidity burden, and valve anatomy, appears to attenuate the mortality signal. This suggests that at least part of the excess risk observed in unmatched analyses may reflect the fact that cancer patients undergoing M-TEER are systematically older, sicker, and more frail than their counterparts, rather than cancer itself being the direct cause of the mortality gap. It is a nuance that will shape how clinicians interpret the headline finding and how they counsel individual patients.

The study also highlights significant gaps in the evidence base. Data on heart failure worsening or hospitalization and on the need for reintervention were insufficient for quantitative synthesis, meaning the analysis could say nothing definitive about whether cancer patients experience more symptomatic recurrence or require more repeat procedures. Only one of the eight included studies assessed surgical mitral valve repair or replacement, so the findings speak almost exclusively to the transcatheter approach. The authors graded the risk of bias in the non-randomized studies using the ROBINS-I tool and the Newcastle-Ottawa Scale, and they are candid that the current evidence is limited by its observational nature and by residual confounding, the ever-present possibility that unmeasured differences between groups explain part of the observed effect.

The context in which this analysis arrives is one of rapidly converging epidemics. Cancer survival has improved dramatically across high-income countries over recent decades, and long-term cancer survivors now number in the tens of millions. Yet cardiovascular disease has emerged as a leading cause of death in this growing population, with several large cohort studies and meta-analyses showing that cardiovascular mortality can rival or even exceed cancer mortality among long-term survivors. Cancer therapies themselves, from anthracycline chemotherapy to mediastinal radiation, accelerate valvular degeneration, myocardial injury, and vascular disease. Valvular heart disease burden has been rising globally, and cardio-oncology, the discipline dedicated to managing the cardiovascular consequences of cancer and its treatment, has been formalized in the 2022 European Society of Cardiology guidelines developed with partner societies across Europe.

For the heart teams that decide between surgery, transcatheter repair, and medical therapy in cancer patients, the new analysis offers both reassurance and caution. The reassurance is that M-TEER can be delivered with equal procedural success and equal short-term safety in patients with cancer, removing one barrier to offering these patients a life-improving intervention. The caution is that the long-term prognosis of these patients remains worse, and the drivers of that excess mortality are unknown. The authors call for prospective cardio-oncology studies designed to improve patient selection and to identify which individuals with cancer are most likely to benefit from transcatheter mitral valve intervention. Until such studies arrive, the clip will keep being deployed, but the question of who truly benefits over the long haul remains open.

Subject of Research: Long-term outcomes of transcatheter mitral valve repair in patients with cancer

Article Title: Long-term outcomes of transcatheter mitral valve repair in patients with cancer: a systematic review and meta-analysis

Article References: Biondi, F., Cadeddu, C., Camilli, M., Cuomo, A., Mandoli, G. E., Minghini, A., Novo, G., & Madonna, R. (2026). Long-term outcomes of transcatheter mitral valve repair in patients with cancer: a systematic review and meta-analysis. GeroScience. https://doi.org/10.1007/s11357-026-02539-7

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02539-7

Keywords: cardio-oncology, transcatheter mitral valve repair, M-TEER, mitral regurgitation, cancer patients, meta-analysis, hazard ratio, heart failure, valvular heart disease, procedural success, long-term mortality, GeroScience